You just read:

U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

News provided by

Janssen Research & Development, LLC

Apr 04, 2017, 07:05 ET